June 5, 2014. As members of the Patient, Consumer, and Public Health Coalition, we strongly support the Research for All Act. It would require the FDA to develop policies to ensure that clinical trials for medical products granted expedited approval are sufficient in design and size to determine the safety and effectiveness for men and women, using subgroup analysis.
Read More »On Health Policy
Letters to Senate Leadership Supporting the Medical Device Excise Tax
June 4, 2014. We thank you for being an outstanding champion of the Affordable Care Act (ACA), and we strongly support your position that a repeal of the 2.3% excise tax on medical devices should not be included in the Tax Extenders Act.
Read More »NCHR Testimony at the FDA Pregnancy Registries Meeting
May 28, 2014. Pregnancy exposure registries tend to be too small and have often not recruited sufficient numbers of racial and ethnic minorities. The biggest challenge is obtaining information on a drug’s safety during pregnancy as quickly as possible after a new drug is marketed.
Read More »NCHR Comments on the Reclassification and Renaming of Shortwave Diathermy
May 21, 2014. The National Center for Health Research strongly opposes the reclassification of the shortwave diathermy (SWD) for any use into class II (special controls).
Read More »Letter to Senator Warren Thanking Her and Other Women Senators for Urging FDA Commissioner Hamburg to Improve Representation in Clinical Research
May 8, 2014. We thanked 15 women Senators for urging FDA Commissioner Margaret Hamburg to improve the representation of women and minorities in clinical research.
Read More »